You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Economic Impact to Employers of Treatment Options for Cardiac Arrhythmias in the US Health System

Kleinman, Nathan L. PhD; Rohrbacker, Nicholas J. MS; White, Sarah A. MPH; March, Jamie L. MBA; Reynolds, Matthew R. MD, MSc

Journal of Occupational & Environmental Medicine:
doi: 10.1097/JOM.0b013e31820fd1c9
Original Articles

Objective: To measure relative employer-sponsored postablation costs for cardiac arrhythmias (CA), specifically atrial fibrillation (AF).

Methods: Regression-Controlled Employee/Spouse Database study (2001 to 2008) comparing CA patients with and without ablation and AF patients with and without ablation. Regression-adjusted monthly medical, pharmacy, sick leave, and short-term disability costs were calculated 11 months before index to 36 months after index (first ablation date or average date for nonablation patients). Relative pre/postindex comparisons between ablation and nonablation cohorts were calculated and time until ablation procedure cost recovery extrapolated.

Results: Few CA (280 of 11,291; 2.48%) and AF (93 of 3062; 3.04%) patients received ablation. Ablation cohorts cost less than nonablation cohorts postablation. Estimated total ablation-period costs were recovered 38 to 50 months postablation, including employee absence payment recovery within 18 months.

Conclusion: Current ablation use in employer-sponsored health plans may improve health care and absence costs over time.

Author Information

From the HCMS Group LLC (Dr Kleinman and Mr Rohrbacker), Cheyenne, Wyo; Biosense Webster, Inc (Ms White and Ms March), Diamond Bar, Calif; and Harvard Clinical Research Institute and Harvard Medical School (Dr Reynolds), Boston, Mass.

Address correspondence to: Nathan L. Kleinman, PhD, 1800 Carey Ave, Ste 500, Cheyenne, WY 82001;

©2011The American College of Occupational and Environmental Medicine